St. Andrew Post-acute Rehabilitation Center | |
16702 North Dale Mabry Hwy, Tampa, Florida 33618 | |
(813) 908-2333 | |
Name | St. Andrew Post-acute Rehabilitation Center |
---|---|
Location | 16702 North Dale Mabry Hwy, Tampa, Florida |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 45 |
Occupancy Rate | 69.56% |
Medicare ID (CCN) | 106015 |
Legal Business Name | Hcp Tampa Fl Opco Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1144797820 |
Organization Name | HCP TAMPA FL OPCO, LLC |
Address | 16702 N Dale Mabry Hwy, Tampa, FL 33618 |
Phone Number | 813-908-2333 |
News Archive
Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare fatal genetic disorder which causes sufferers to age prematurely.
NewLink Genetics Corporation announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a pivotal Phase 3 trial of its HyperAcute immunotherapy in pancreatic cancer. Pancreatic cancer is highly lethal and is currently an area of very significant unmet medical need. The SPA is a written agreement between NewLink as the trial sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of a Phase 3 trial to be used in support of a Biologic License Application (BLA).
Alliance Healthcare Foundation announced today the recipients of nearly $1,000,000 in Mission Support Grants. AHF is committed to serving the most vulnerable populations in the San Diego area through funding projects and programs that address access to healthcare, with a focus on increasing the capacity and coordination of the healthcare delivery system.
A group of researchers from University of Toronto Engineering and SickKids Hospital have developed a new way to deliver molecules that target specific genes within cells.
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported the completion of patient randomization for its ANCHOR trial, a pivotal Phase 3 trial of AMR101. The Company indicated that it anticipates reporting top-line results from this trial in Q2 2011.
› Verified 5 days ago
NPI Number | 1699728626 |
Organization Name | SOLOMON HOLDINGS I - THE TRIANGLE LLC |
Doing Business As | BRIGHTON GARDEN OF TAMPA |
Address | 16702 N Dale Mabry Hwy, Tampa, FL 33618 |
Phone Number | 813-908-2333 |
News Archive
Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare fatal genetic disorder which causes sufferers to age prematurely.
NewLink Genetics Corporation announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a pivotal Phase 3 trial of its HyperAcute immunotherapy in pancreatic cancer. Pancreatic cancer is highly lethal and is currently an area of very significant unmet medical need. The SPA is a written agreement between NewLink as the trial sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of a Phase 3 trial to be used in support of a Biologic License Application (BLA).
Alliance Healthcare Foundation announced today the recipients of nearly $1,000,000 in Mission Support Grants. AHF is committed to serving the most vulnerable populations in the San Diego area through funding projects and programs that address access to healthcare, with a focus on increasing the capacity and coordination of the healthcare delivery system.
A group of researchers from University of Toronto Engineering and SickKids Hospital have developed a new way to deliver molecules that target specific genes within cells.
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported the completion of patient randomization for its ANCHOR trial, a pivotal Phase 3 trial of AMR101. The Company indicated that it anticipates reporting top-line results from this trial in Q2 2011.
› Verified 5 days ago
NPI Number | 1841878501 |
Organization Name | TAMPA FL OPCO LLC |
Doing Business As | ST ANDREW POST-ACUTE AND REHABILITATION CENTER |
Address | 16702 N Dale Mabry Hwy, Tampa, FL 33618 |
Phone Number | 813-908-2333 |
News Archive
Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare fatal genetic disorder which causes sufferers to age prematurely.
NewLink Genetics Corporation announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a pivotal Phase 3 trial of its HyperAcute immunotherapy in pancreatic cancer. Pancreatic cancer is highly lethal and is currently an area of very significant unmet medical need. The SPA is a written agreement between NewLink as the trial sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of a Phase 3 trial to be used in support of a Biologic License Application (BLA).
Alliance Healthcare Foundation announced today the recipients of nearly $1,000,000 in Mission Support Grants. AHF is committed to serving the most vulnerable populations in the San Diego area through funding projects and programs that address access to healthcare, with a focus on increasing the capacity and coordination of the healthcare delivery system.
A group of researchers from University of Toronto Engineering and SickKids Hospital have developed a new way to deliver molecules that target specific genes within cells.
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported the completion of patient randomization for its ANCHOR trial, a pivotal Phase 3 trial of AMR101. The Company indicated that it anticipates reporting top-line results from this trial in Q2 2011.
› Verified 5 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare fatal genetic disorder which causes sufferers to age prematurely.
NewLink Genetics Corporation announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a pivotal Phase 3 trial of its HyperAcute immunotherapy in pancreatic cancer. Pancreatic cancer is highly lethal and is currently an area of very significant unmet medical need. The SPA is a written agreement between NewLink as the trial sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of a Phase 3 trial to be used in support of a Biologic License Application (BLA).
Alliance Healthcare Foundation announced today the recipients of nearly $1,000,000 in Mission Support Grants. AHF is committed to serving the most vulnerable populations in the San Diego area through funding projects and programs that address access to healthcare, with a focus on increasing the capacity and coordination of the healthcare delivery system.
A group of researchers from University of Toronto Engineering and SickKids Hospital have developed a new way to deliver molecules that target specific genes within cells.
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported the completion of patient randomization for its ANCHOR trial, a pivotal Phase 3 trial of AMR101. The Company indicated that it anticipates reporting top-line results from this trial in Q2 2011.
› Verified 5 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 1 |
Total Amount of Fines in Dollars | $10342 |
Number of Payment Denials | 0 |
Total Number of Penalties | 1 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 17.31 | 14.46 |
Percentage of long-stay residents who lose too much weight | 7.84 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 66.67 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 2.74 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 0 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 13.64 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 17.31 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 30.91 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 7.94 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 95 | 95.98 |
Percentage of short-stay residents who made improvements in function | 54.05 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 97.17 | 82.93 |
News Archive
Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare fatal genetic disorder which causes sufferers to age prematurely.
NewLink Genetics Corporation announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a pivotal Phase 3 trial of its HyperAcute immunotherapy in pancreatic cancer. Pancreatic cancer is highly lethal and is currently an area of very significant unmet medical need. The SPA is a written agreement between NewLink as the trial sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of a Phase 3 trial to be used in support of a Biologic License Application (BLA).
Alliance Healthcare Foundation announced today the recipients of nearly $1,000,000 in Mission Support Grants. AHF is committed to serving the most vulnerable populations in the San Diego area through funding projects and programs that address access to healthcare, with a focus on increasing the capacity and coordination of the healthcare delivery system.
A group of researchers from University of Toronto Engineering and SickKids Hospital have developed a new way to deliver molecules that target specific genes within cells.
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported the completion of patient randomization for its ANCHOR trial, a pivotal Phase 3 trial of AMR101. The Company indicated that it anticipates reporting top-line results from this trial in Q2 2011.
› Verified 5 days ago
Bristol At Tampa Rehab And Nursing Center Llc Location: 1818 E Fletcher Ave, Tampa, Florida 33612 Phone: (813) 971-2383 | |
Rehabilitation And Healthcare Center Of Tampa Location: 4411 N Habana Ave, Tampa, Florida 33614 Phone: (813) 872-2771 | |